Compile Data Set for Download or QSAR
Report error Found 39 Enz. Inhib. hit(s) with all data for entry = 1819
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342101(US9771353, Example 1 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342108(US9771353, Example 8 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342101(US9771353, Example 1 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342102(US9771353, Example 2 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342107(US9771353, Example 7 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342110(US9771353, Example 10 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342110(US9771353, Example 10 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 9nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342111(US9771353, Example 11 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 9nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342105(US9771353, Example 5 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 10nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342102(US9771353, Example 2 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342107(US9771353, Example 7 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342111(US9771353, Example 11 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 13nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342108(US9771353, Example 8 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342103(US9771353, Example 3 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 36nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342109(US9771353, Example 9 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 53nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342109(US9771353, Example 9 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 66nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342101(US9771353, Example 1 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 149nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 12(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342105(US9771353, Example 5 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 160nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342101(US9771353, Example 1 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 499nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342102(US9771353, Example 2 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 543nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342110(US9771353, Example 10 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 819nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342111(US9771353, Example 11 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 1.00E+3nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342109(US9771353, Example 9 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342108(US9771353, Example 8 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342107(US9771353, Example 7 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342105(US9771353, Example 5 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 1.00E+3nMAssay Description:GSK 3α: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determinin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342104(US9771353, Example 4 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.01E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342106(US9771353, Example 6 | 1-(4-((2-((3-(2,5,8,11,14,1...)
Affinity DataIC50: 1.23E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342107(US9771353, Example 7 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.85E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342103(US9771353, Example 3 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 1.94E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342108(US9771353, Example 8 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 3.07E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342102(US9771353, Example 2 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 5.23E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342105(US9771353, Example 5 | 1-(3-(tert-Butyl)-1-methyl-...)
Affinity DataIC50: 7.49E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342113(US9771353, Example 13(a) | 3-((4-((4-(3-(3-(tert-B...)
Affinity DataIC50: 8.61E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342111(US9771353, Example 11 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 9.52E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342109(US9771353, Example 9 | 3-((4-((4-(3-(3-(tert-Butyl...)
Affinity DataIC50: 1.24E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342112(US9771353, Example 12 | 3-((4-((4-(3-(1,3-Di-tert-...)
Affinity DataIC50: 1.31E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342114(US9771353, Example 13(b) | 3-((4-((4-(3-(3-(tert-B...)
Affinity DataIC50: 1.31E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM342110(US9771353, Example 10 | 3-Ethynyl-5-((4-((4-(3-(3-...)
Affinity DataIC50: 1.41E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3-alpha enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2019
Entry Details
Go to US Patent